WEKO3
アイテム
Pharmacokinetic Drug Interaction Between Rosuvastatin and Tanjin in Healthy Volunteers and Rats
https://repository.lib.tottori-u.ac.jp/records/4772
https://repository.lib.tottori-u.ac.jp/records/47723925e8bb-abd1-443c-baf0-25225fc4e00b
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
yam62(1)_77.pdf (1.1 MB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2019-06-17 | |||||||||||
| タイトル | ||||||||||||
| タイトル | Pharmacokinetic Drug Interaction Between Rosuvastatin and Tanjin in Healthy Volunteers and Rats | |||||||||||
| 言語 | en | |||||||||||
| 言語 | ||||||||||||
| 言語 | eng | |||||||||||
| キーワード | ||||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | absorption | |||||||||||
| キーワード | ||||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | drug interactions | |||||||||||
| キーワード | ||||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | herbal medicine | |||||||||||
| キーワード | ||||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | pharmacokinetics | |||||||||||
| キーワード | ||||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | rosuvastatin | |||||||||||
| キーワード | ||||||||||||
| 言語 | en | |||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | absorption | |||||||||||
| キーワード | ||||||||||||
| 言語 | en | |||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | drug interactions | |||||||||||
| キーワード | ||||||||||||
| 言語 | en | |||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | herbal medicine | |||||||||||
| キーワード | ||||||||||||
| 言語 | en | |||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | pharmacokinetics | |||||||||||
| キーワード | ||||||||||||
| 言語 | en | |||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | rosuvastatin | |||||||||||
| 資源タイプ | ||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||
| 資源タイプ | journal article | |||||||||||
| 著者 |
Yang, Jie
× Yang, Jie× Hasegawa, Junichi× Endo, Yusuke× Iitsuka, Kazuhiko× Yamamoto, Miwa
WEKO
4738
× Matsuda, Akiko× Yang, Jie× Hasegawa, Junichi× Iitsuka, Kazuhiko× Matsuda, Akiko |
|||||||||||
| 著者所属 | ||||||||||||
| 値 | Division of Pharmacology, School of Medicine, Tottori University Faculty of Medicine | |||||||||||
| 著者所属 | ||||||||||||
| 値 | National Hospital Organization Yonago Medical Center | |||||||||||
| 著者所属 | ||||||||||||
| 値 | Advanced Medicine, Innovation and Clinical Research Center, Tottori University Hospital | |||||||||||
| 著者所属 | ||||||||||||
| 値 | Division of Pharmacology, School of Medicine, Tottori University Faculty of Medicine | |||||||||||
| 著者所属 | ||||||||||||
| 値 | Department of Adult and Elderly Nursing, School of Health of Science, Tottori University Faculty of Medicine | |||||||||||
| 著者所属 | ||||||||||||
| 値 | Faculty of Nursing, Nara Medical University | |||||||||||
| 著者所属（英） | ||||||||||||
| 言語 | en | |||||||||||
| 値 | Division of Pharmacology, School of Medicine, Tottori University Faculty of Medicine | |||||||||||
| 著者所属（英） | ||||||||||||
| 言語 | en | |||||||||||
| 値 | National Hospital Organization Yonago Medical Center | |||||||||||
| 著者所属（英） | ||||||||||||
| 言語 | en | |||||||||||
| 値 | Advanced Medicine, Innovation and Clinical Research Center, Tottori University Hospital | |||||||||||
| 著者所属（英） | ||||||||||||
| 言語 | en | |||||||||||
| 値 | Division of Pharmacology, School of Medicine, Tottori University Faculty of Medicine | |||||||||||
| 著者所属（英） | ||||||||||||
| 言語 | en | |||||||||||
| 値 | Department of Adult and Elderly Nursing, School of Health of Science, Tottori University Faculty of Medicine | |||||||||||
| 著者所属（英） | ||||||||||||
| 言語 | en | |||||||||||
| 値 | Faculty of Nursing, Nara Medical University | |||||||||||
| 抄録 | ||||||||||||
| 内容記述タイプ | Other | |||||||||||
| 内容記述 | [Background] Tanjin is an herbal medicine made from the root of salvia miltiorrhiza. It is predominantly given to arteriosclerotic patients as a supplement to ameliorate the clinical symptoms of cardiovascular diseases. In China, tanjin is used frequently in combination treatment for hypercholesterolemia. Thus, there is a high probability of combination of tanjin and statins in these arteriosclerotic patients. This study investigated the interaction between tanjin and rosuvastatin. [Methods] We performed a randomized single-blind, two-period crossover clinical trial on six healthy male volunteers. Volunteers were administered rosuvastatin with placebo or a tanjin-containing drug randomly. The blood samples were collected before drug administration, and at 0.5, 1, 1.5, 2, 4, 8, and 12 hours after administration. Lymphocytes were isolated from blood samples before and 12 hours after drug administration to measure mRNA. As an animal experiment, an in situ intestinal injection with portal vein sampling model was used to examine the interaction between tanjin and rosuvastatin during the absorption phase. Rosuvastatin or rosuvastatin combined with tanjin solution was injected into the intestine. After injection, blood from the portal vein was collected and the concentration of rosuvastatin was measured by LC/MS/MS analysis. A portion of the intestine and liver from the rats was collected and stored at -80°C for mRNA measurement. [Results] In the clinical trial, co-administration of tanjin decreased the maximum plasma concentration (Cmax) of rosuvastatin by 26.85% compared with rosuvastatin alone, and also decreased the area under the plasma concentration-time curve of rosuvastatin from 0 to 12 h (AUC0?12) by 19.43%. The relative expression of BCRP and OATP mRNA in human lymphocytes was increased by co-administration of tanjin. In the animal experiment, co-administration of tanjin extract reduced the concentration of rosuvastatin to 84.4, 64.4, and 50.0% at 15, 30, and 45 minutes, respectively. The tanjin-containing drug had a similar effect to tanjin extract. Furthermore, tanjin significantly reduced the absorption of rosuvastatin and the inhibitory effects lasted for at least 24 hours. Tanjin increased the relative expression of BCRP mRNA in the intestine, but it did not change the expression of OATP. Moreover, the concentration of rosuvastatin in the portal vein and systemic blood was reduced. In the liver, tanjin increased both BCRP and OATP mRNA expression, which was consistent with the results from human lymphocytes. [Conclusion] The clinical trial and animal experiment revealed that tanjin can significantly reduce the absorption of rosuvastatin. This interaction occurred, at least, at the absorption phase in the small intestine due to the enhanced efflux transport. Thus, as tanjin and rosuvastatin were found to interact, their combination needs to be paid attention to. | |||||||||||
| 書誌情報 |
Yonago Acta Medica en : Yonago Acta Medica 巻 62, 号 1, p. 77-84, 発行日 2019-03-28 |
|||||||||||
| 出版者 | ||||||||||||
| 出版者 | Tottori University Medical Press | |||||||||||
| ISSN | ||||||||||||
| 収録物識別子タイプ | ISSN | |||||||||||
| 収録物識別子 | 05135710 | |||||||||||
| 書誌レコードID | ||||||||||||
| 収録物識別子タイプ | NCID | |||||||||||
| 収録物識別子 | AA00892882 | |||||||||||
| DOI | ||||||||||||
| 関連タイプ | isIdenticalTo | |||||||||||
| 識別子タイプ | DOI | |||||||||||
| 関連識別子 | 10.33160/yam.2019.03.011 | |||||||||||
| 権利 | ||||||||||||
| 権利情報 | Yonago Acta medica 編集委員会 | |||||||||||
| 情報源 | ||||||||||||
| 関連名称 | Yonago Acta Medica. 2019, 62(1), 77-84 | |||||||||||
| 関連サイト | ||||||||||||
| 識別子タイプ | URI | |||||||||||
| 関連識別子 | https://www.jstage.jst.go.jp/article/yam/62/1/62_2019.03.011/_article/-char/en | |||||||||||
| 関連名称 | https://www.jstage.jst.go.jp/article/yam/62/1/62_2019.03.011/_article/-char/en | |||||||||||
| 関連サイト | ||||||||||||
| 識別子タイプ | URI | |||||||||||
| 関連識別子 | http://www.lib.tottori-u.ac.jp/yam/yam/yam62-1/62-1contents.html | |||||||||||
| 関連名称 | http://www.lib.tottori-u.ac.jp/yam/yam/yam62-1/62-1contents.html | |||||||||||
| 著者版フラグ | ||||||||||||
| 出版タイプ | VoR | |||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||||
| EISSN | ||||||||||||
| 値 | 1346-8049 | |||||||||||
